BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
BioXcel Therapeutics 公佈了其即將推出的用於治療阿爾茨海默氏癡呆相關焦慮的 BXCL501 TRANQUILITY In-care 3 期試驗的計劃設計細節